Sentiment-Signal
18,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 30.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; App |
Stammdaten
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Unternehmen & Branche
| Name | Vir Biotechnology, Inc. |
|---|---|
| Ticker | VIR |
| CIK | 0001706431 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,65 Mrd. USD |
| Beta | 1,66 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 68,556,000 | -437,987,000 | -3.16 | 1,002,823,000 | |
| 2025-09-30 | 10-Q | 240,000 | -163,141,000 | -1.17 | 1,019,453,000 | 796,098,000 |
| 2025-06-30 | 10-Q | 1,214,000 | -110,958,000 | -0.80 | 1,192,532,000 | 947,472,000 |
| 2025-03-31 | 10-Q | 3,032,000 | -120,965,000 | -0.88 | 1,307,727,000 | 1,043,819,000 |
| 2024-12-31 | 10-K | 74,205,000 | -521,960,000 | -3.83 | 1,398,813,000 | |
| 2024-09-30 | 10-Q | 2,380,000 | -213,717,000 | -1.56 | 1,498,356,000 | 1,240,727,000 |
| 2024-06-30 | 10-Q | 3,075,000 | -138,378,000 | -1.02 | 1,669,555,000 | 1,433,670,000 |
| 2024-03-31 | 10-Q | 56,376,000 | -65,276,000 | -0.48 | 1,793,969,000 | 1,547,356,000 |
| 2023-12-31 | 10-K | 86,180,000 | -615,061,000 | -4.59 | 1,919,060,000 | |
| 2023-09-30 | 10-Q | 2,639,000 | -163,413,000 | -1.22 | 2,044,895,000 | |
| 2023-06-30 | 10-Q | 3,797,000 | -194,775,000 | -1.45 | 2,243,874,000 | |
| 2023-03-31 | 10-Q | 62,957,000 | -140,956,000 | -1.06 | 2,665,936,000 | 1,970,757,000 |
| 2022-12-31 | 10-K | 1,615,797,000 | 515,837,000 | 3.83 | 2,802,088,000 | 2,077,963,000 |
| 2022-09-30 | 10-Q | 374,557,000 | 175,312,000 | 1.30 | 2,695,970,000 | 2,149,855,000 |
| 2022-06-30 | 10-Q | -40,629,000 | -76,493,000 | -0.58 | 2,618,994,000 | 1,952,012,000 |
| 2022-03-31 | 10-Q | 1,232,459,000 | 518,621,000 | 3.85 | 2,887,129,000 | 2,001,014,000 |
| 2021-12-31 | 10-K | 1,095,415,000 | 528,584,000 | 3.96 | 1,954,268,000 | 1,431,849,000 |
| 2021-09-30 | 10-Q | 103,616,000 | 110,428,000 | 0.82 | 1,210,213,000 | 876,274,000 |
| 2021-06-30 | 10-Q | 177,068,000 | 61,813,000 | 0.46 | 1,057,581,000 | 737,325,000 |
| 2021-03-31 | 10-Q | 1,976,000 | -168,911,000 | -1.32 | 1,135,584,000 | 650,951,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | De Backer Marianne | Director, Officer, President and CEO | Open Market Sale | -72,559 | 9.16 | -664,350.20 | -172,7% | |
| 2026-04-01 | SATO VICKI L | Director | Open Market Sale | -22,000 | 9.07 | -199,617.00 | -51,9% | |
| 2026-03-23 | Sabatini Brent | Officer, SVP, Chief Accounting Officer | Open Market Sale | -7,711 | 9.12 | -70,324.32 | -18,3% | |
| 2026-03-02 | SATO VICKI L | Director | Open Market Sale | -21,800 | 9.50 | -207,185.02 | -53,9% | |
| 2026-03-02 | SATO VICKI L | Director | Open Market Sale | -200 | 9.98 | -1,996.00 | -0,5% | |
| 2026-02-25 | de Verneuil Vanina | Officer, EVP, General Counsel, Corp Sec | Open Market Sale | -13,700 | 9.82 | -134,534.00 | -35,0% | |
| 2026-02-25 | Eisner Mark | Officer, EVP and Chief Medical Officer | Open Market Sale | -1,889 | 9.82 | -18,549.98 | -4,8% | |
| 2026-02-24 | SATO VICKI L | Director | Open Market Sale | -200 | 10.26 | -2,052.00 | -0,5% | |
| 2026-02-24 | Sabatini Brent | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,430 | 9.53 | -13,631.62 | -3,5% | |
| 2026-02-24 | de Verneuil Vanina | Officer, EVP, General Counsel, Corp Sec | Open Market Sale | -3,117 | 9.53 | -29,713.11 | -7,7% | |
| 2026-02-24 | Eisner Mark | Officer, EVP and Chief Medical Officer | Open Market Sale | -1,616 | 9.53 | -15,404.68 | -4,0% | |
| 2026-02-24 | De Backer Marianne | Director, Officer, Chief Executive Officer | Open Market Sale | -14,762 | 9.53 | -140,720.24 | -36,6% | |
| 2026-02-24 | SATO VICKI L | Director | Open Market Sale | -42,177 | 9.75 | -411,314.32 | -107,0% | |
| 2026-02-24 | O'Byrne Jason | Officer, EVP & Chief Financial Officer | Open Market Sale | -1,634 | 9.53 | -15,576.27 | -4,1% | |
| 2026-02-23 | O'Byrne Jason | Officer, EVP & Chief Financial Officer | Open Market Sale | -2,089 | 7.45 | -15,568.90 | -4,0% | |
| 2026-02-23 | de Verneuil Vanina | Officer, EVP, General Counsel, Corp Sec | Open Market Sale | -4,445 | 7.45 | -33,127.70 | -8,6% | |
| 2026-02-23 | Eisner Mark | Officer, EVP and Chief Medical Officer | Open Market Sale | -2,089 | 7.45 | -15,568.90 | -4,0% | |
| 2026-02-23 | Sabatini Brent | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,829 | 7.45 | -13,631.17 | -3,5% | |
| 2026-02-23 | De Backer Marianne | Director, Officer, Chief Executive Officer | Open Market Sale | -19,039 | 7.45 | -141,893.86 | -36,9% | |
| 2026-02-13 | Sabatini Brent | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,530 | 7.79 | -11,918.70 | -3,1% | |
| 2026-02-02 | SATO VICKI L | Director | Open Market Sale | -22,000 | 7.71 | -169,670.60 | -44,1% | |
| 2026-01-02 | SATO VICKI L | Director | Open Market Sale | -22,000 | 5.93 | -130,383.00 | -33,9% | |
| 2025-12-01 | SATO VICKI L | Director | Open Market Sale | -22,000 | 6.00 | -132,070.40 | -34,3% | |
| 2025-12-01 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -191,854 | 5.98 | -1,147,785.74 | -298,5% | |
| 2025-11-28 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -61,493 | 6.44 | -396,014.92 | -103,0% | |
| 2025-11-26 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -127,938 | 6.39 | -817,651.76 | -212,6% | |
| 2025-11-25 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -235,971 | 6.38 | -1,505,494.98 | -391,5% | |
| 2025-11-24 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -227,803 | 6.15 | -1,400,783.43 | -364,2% | |
| 2025-11-17 | O'Byrne Jason | Officer, EVP & Chief Financial Officer | Open Market Sale | -6,799 | 5.56 | -37,782.04 | -9,8% | |
| 2025-11-05 | de Verneuil Vanina | Officer, EVP, General Counsel, Corp Sec | Open Market Sale | -2,385 | 5.16 | -12,306.60 | -3,2% | |
| 2025-11-03 | de Verneuil Vanina | Officer, EVP and General Counsel | Open Market Sale | -1,365 | 5.86 | -8,003.00 | -2,1% | |
| 2025-11-03 | SATO VICKI L | Director | Open Market Sale | -22,000 | 5.64 | -124,047.00 | -32,3% | |
| 2025-10-29 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -100 | 6.49 | -649.00 | -0,2% | |
| 2025-10-28 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -24,453 | 6.50 | -159,005.63 | -41,3% | |
| 2025-10-27 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -66,403 | 6.05 | -401,585.42 | -104,4% | |
| 2025-10-24 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -46,696 | 5.96 | -278,284.81 | -72,4% | |
| 2025-10-23 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -154,383 | 5.99 | -924,723.29 | -240,5% | |
| 2025-10-22 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -144,266 | 6.15 | -887,654.27 | -230,8% | |
| 2025-10-21 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -109,675 | 6.30 | -690,974.44 | -179,7% | |
| 2025-10-20 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -220,535 | 6.20 | -1,367,272.89 | -355,5% | |
| 2025-10-16 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -12,844 | 6.10 | -78,366.38 | -20,4% | |
| 2025-10-15 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -16,671 | 6.07 | -101,196.30 | -26,3% | |
| 2025-10-10 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -2,300 | 6.08 | -13,972.96 | -3,6% | |
| 2025-10-09 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -249,060 | 6.14 | -1,529,925.77 | -397,8% | |
| 2025-10-08 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -466,242 | 6.05 | -2,819,784.99 | -733,2% | |
| 2025-10-07 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -72,133 | 5.60 | -404,153.99 | -105,1% | |
| 2025-10-06 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -73,955 | 5.69 | -420,641.25 | -109,4% | |
| 2025-10-03 | SVF Endurance (Cayman) Ltd | 10% Owner | Open Market Sale | -450,342 | 5.56 | -2,501,784.91 | -650,5% | |
| 2025-10-01 | SATO VICKI L | Director | Open Market Sale | -22,000 | 5.84 | -128,396.40 | -33,4% | |
| 2025-09-02 | SATO VICKI L | Director | Open Market Sale | -22,000 | 4.99 | -109,810.80 | -28,6% | |
| 2025-08-01 | SATO VICKI L | Director | Open Market Sale | -22,000 | 4.99 | -109,698.60 | -28,5% | |
| 2025-07-17 | Eisner Mark | Officer, EVP and Chief Medical Officer | Open Market Sale | -3,586 | 5.47 | -19,629.05 | -5,1% | |
| 2025-07-15 | Eisner Mark | Officer, EVP and Chief Medical Officer | Open Market Sale | -6,796 | 5.47 | -37,161.89 | -9,7% | |
| 2025-07-01 | SATO VICKI L | Director | Open Market Sale | -22,000 | 5.10 | -112,206.60 | -29,2% | |
| 2025-06-02 | Napolitano Janet | Director | Open Market Sale | -3,200 | 5.05 | -16,148.80 | -4,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.